Skip to main content
Clinical Trials/JPRN-jRCTb030220370
JPRN-jRCTb030220370SuspendedPhase 2

Feasibility study of periodontal tissue regene ration using the combination of adipose-derived stem cells, platelet-rich plasma and autologous bone transplantation

Tobita Morikuni0 sites10 target enrollmentStarted: October 7, 2022Last updated:
Conditions

Trial Snapshot

Phase
Phase 2
Status
Suspended
Sponsor
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to ot applicable (—)
Sex
All

Inclusion Criteria

  • (1) Teeth that have been diagnosed with marginal periodontitis andthe dentist has determined that flap surgery is necessary.
  • (2) Vertical bone defects with a probing depth of 6 mm or more and adepth of 5 mm or more are found in the mesial or distal side of thetarget tooth.
  • (3) Teeth with keratinized gingivadetermined to be suitable for flapsurgery with a tooth mobility of 2 degrees or less.
  • (4) Patients who are capable of oral hygienemanagement.
  • (5) Must be able to perform normal subcutaneous fat tissue sampling.
  • (6) 20 years of age or older at the time of obtaining consent.
  • (7) Patients who have consented in writing to participate in thisclinical trial.

Exclusion Criteria

  • (1) Teeth for which it is impossible to measure the clinical attachmentlevel
  • (2) Patients with concomitant or history of malignancy
  • (3) Patients with malignant tumors, allcancerous lesions, or suspiciousfindings in the pre-registration oral examination
  • (4) Patients who have been diagnosed with osteoporosis.
  • (5) Teeth with concomitant diseases other than marginal periodontitisthat may affect periodontal tissue regeneration therapy (periodontitis,root fracture, etc.)
  • (6) Tooth that is scheduled to undergo a procedure (surgical treatment,prosthetic treatment, root canal treatment, etc.) that may affect theevaluation of the implantation site within 36 weeks after implantation
  • (7) Pregnant, lactating, possibly pregnant according to a pregnancytest prior to enrollment, or planning to become pregnant within 36weeks of implantation
  • (8) Patients with serious hematological diseases or abnormal bonemetabolism
  • (9) Patients with abnormalities in the kidney, digestive organs, orother organs of calcium metabolism, or suspected collagen disease.
  • (10) Patients on dialysis or receiving steroids.
  • (11) Patients with unmanageable complications that limit compliancewith clinical research requirements, such as serious complications (e.g.,serious heart disease, liver disease) or psychiatric disorders.
  • (12) Patients with a blood hemoglobin A1c of 6.8% or higher prior toenrollment
  • (13) Patients with active infections
  • (14) Patients with a history of alcohol ordrug intoxication
  • (15) Those who are positive for HCV antibody, HBs antigen, ATLAvirus antibody, or HIV antibody
  • (16) Smokers (average of 10 cigarettes/day or more)
  • (17) Those who, in the judgment of the principal investigator, areconsidered inappropriateto participate in this research.

Investigators

Sponsor
Tobita Morikuni

Similar Trials